Longeveron (Nasdaq:LGVN) - Cotización, noticias y análisis

Resumen de acción LGVN

Longeveron Inc, empresa biotecnológica en fase clínica, desarrolla terapias celulares para enfermedades relacionadas con el envejecimiento y potencialmente mortales en Estados Unidos y Japón.

Acerca de la empresa

LGVN fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 98.2% por debajo de nuestra estimación de su valor justo

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene unos ingresos inferiores a 1 millón de dólares ($709K)

No tiene una capitalización de mercado significativa ($12M)

+ 1 riesgos adicionales

Competidores de Longeveron Inc.

Inhibikase Therapeutics

NasdaqCM:IKT

US$12.3m

Oncternal Therapeutics

NasdaqCM:ONCT

US$22.2m

SAB Biotherapeutics

NasdaqCM:SABS

US$37.0m

OncoCyte

NasdaqCM:OCX

US$32.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Longeveron
Historical stock prices
Current Share Price	US$1.67
52 Week High	US$44.00
52 Week Low	US$1.60
Beta	0.20
1 Month Change	-51.41%
3 Month Change	-79.13%
1 Year Change	-94.06%
3 Year Change	-97.26%
5 Year Change	n/a
Change since IPO	-97.75%

Noticias y actualizaciones recientes

Recent updates

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Jul 07

Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market

May 06

Companies Like Longeveron (NASDAQ:LGVN) Are In A Position To Invest In Growth

Apr 03

Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses

Feb 15

Longeveron: Spooky Social-Media Generated Spike Signifies Nothing

Nov 29

Is Longeveron (NASDAQ:LGVN) In A Good Position To Deliver On Growth Plans?

Nov 20

Rentabilidad de los accionistas

	LGVN	US Biotechs	Mercado US
7D	-16.9%	0.4%	1.0%
1Y	-94.1%	0.9%	21.9%

Rentabilidad vs. Industria: LGVN obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 0.7%.

Rentabilidad vs. Mercado: LGVN obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is LGVN's price volatile compared to industry and market?
LGVN volatility
LGVN Average Weekly Movement	28.9%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de LGVN ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de LGVN ha aumentado de 18% a 29% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	24	Mohamed Wa'el Hashad	longeveron.com

Longeveron Inc, empresa biotecnológica en fase clínica, desarrolla terapias celulares para enfermedades relacionadas con el envejecimiento y potencialmente mortales en Estados Unidos y Japón. El principal producto en investigación de la empresa es el LOMECEL-B, una formulación de células madre mesenquimales alogénicas procedentes de la médula ósea de donantes adultos jóvenes y sanos. Está llevando a cabo ensayos clínicos de fase 1, fase 1/2, fase 2a y fase 2b en diversas indicaciones, como la fragilidad relacionada con el envejecimiento, la enfermedad de Alzheimer y el síndrome del corazón izquierdo hipoplásico.

Resumen de fundamentos de Longeveron Inc.

¿Cómo se comparan los beneficios e ingresos de Longeveron con su capitalización de mercado?
Estadísticas fundamentales de LGVN
Capitalización bursátil	US$12.02m
Beneficios(TTM)	-US$22.21m
Ingresos (TTM)	US$709.00k

17.0x

Ratio precio-ventas (PS)

-0.5x

Ratio precio-beneficio (PE)

¿Está LGVN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de LGVN
Ingresos	US$709.00k
Coste de los ingresos	US$488.00k
Beneficio bruto	US$221.00k
Otros gastos	US$22.43m
Beneficios	-US$22.21m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.09
Margen bruto	31.17%
Margen de beneficio neto	-3,132.72%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado LGVN a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción LGVN

Recompensas

Análisis de riesgos

Competidores de Longeveron Inc.

NasdaqCM:IKT

US$12.3m

NasdaqCM:ONCT

US$22.2m

NasdaqCM:SABS

US$37.0m

NasdaqCM:OCX

US$32.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Recent updates

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Full year 2023 earnings: EPS misses analyst expectations

Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million.

Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease

Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%

Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease

Director exercised options to buy US$70k worth of stock.

New major risk - Revenue size

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023

Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023

Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer

High number of new directors

Longeveron Inc. Approves Bord Appointments

Longeveron Inc. Announces Resignation of James Clavijo as CFO

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021)

Price target decreased to US$15.50

Longeveron Provides Corporate Update

Consensus forecasts updated

Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Longeveron Inc. Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’S Disease

Longeveron Inc. to Report Q3, 2022 Results on Nov 14, 2022

Longeveron Inc.: A New Approach To Treat Alzheimer's

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B(TM) Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants

Longeveron spikes after FDA’s Fast Track Designation for lead candidate

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.26 loss in 2Q 2021)

Longeveron Inc. to Report Q2, 2022 Results on Aug 12, 2022

Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Director notifies of intention to sell stock

CFO & Treasurer recently sold US$305k worth of stock

Director recently sold US$153k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Longeveron Inc. to Report Q1, 2022 Results on May 13, 2022

Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market

High number of new directors

Longeveron Inc. Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial

Longeveron Inc. Appoints K. Chris Min as Chief Medical Officer